FDA Warns Of Diabetes Drugs From AstraZeneca, Janssen

By Jeff Overley (May 15, 2015, 3:44 PM EDT) -- The U.S. Food and Drug Administration on Friday warned of serious blood problems linked to use of six diabetes drugs, including AstraZeneca PLC's Farxiga and Janssen Pharmaceuticals Inc.'s Invokana.

In a safety alert, the FDA announced receiving 20 reports from March 2013 to June 2014 of so-called diabetic ketoacidosis — a disorder involving elevated levels of blood acids known as ketones — in patients using the six drugs. Every patient had to be hospitalized or visit the emergency room, and other patients have continued to be affected in ensuing months, regulators said.

The afflictions were unusual because they mainly occurred in...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!